Generating double knockout mice to model genetic intervention for diabetic cardiomyopathy in humans

Methods in Molecular Biology

Volumn 1194, Issue , 2014, Pages 385-400

  Chavali, Vishalakshi ^a   Nandi, Shyam Sundar ^a   Singh, Shree Ram ^b   Mishra, Paras Kumar ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Diabetes; Heart failure; Mmp9

Indexed keywords

ATRIAL NATRIURETIC FACTOR; GELATINASE B; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN 2; UNCLASSIFIED DRUG; WHEAT GERM AGGLUTININ; DNA; INS2 PROTEIN, MOUSE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 2; CONTROLLED STUDY; CROSS BREEDING; DIABETIC CARDIOMYOPATHY; DNA EXTRACTION; ELECTRIC CURRENT; EXTRACELLULAR MATRIX; FEMALE; GENE INACTIVATION; GENE OVEREXPRESSION; GENE THERAPY; GENETIC MODEL; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART FAILURE; HEART MUSCLE FIBROSIS; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ZYMOGRAPHY; AGAR GEL ELECTROPHORESIS; ANIMAL; CELL MEMBRANE; DIABETIC CARDIOMYOPATHIES; GENETICS; GENOTYPING TECHNIQUE; HUMAN; HYBRIDIZATION; HYPERTROPHY; ISOLATION AND PURIFICATION; METABOLISM; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES;

ANIMALS; BLOTTING, WESTERN; CELL MEMBRANE; DIABETIC CARDIOMYOPATHIES; DNA; ELECTROPHORESIS, AGAR GEL; FEMALE; GENE KNOCKOUT TECHNIQUES; GENETIC THERAPY; GENOTYPING TECHNIQUES; HUMANS; HYBRIDIZATION, GENETIC; HYPERTROPHY; INSULIN; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MUTATION; POLYMERASE CHAIN REACTION; WHEAT GERM AGGLUTININS;

EID: 84925884075     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1215-5_22     Document Type: Article

References (32)

1. Wild S, Roglic G, Green A, Sicree R, King H. (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053
2. Chavali V, Tyagi SC, Mishra PK. (2013) Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes 6:151-160
3. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr. (2004) Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: A report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 109:476-480
4. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientifi c statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 33:1395-1402
5. Rota M, LeCapitaine N, Hosoda T, Boni A, De AA, Padin-Iruegas ME, Esposito G, Vitale S, Urbanek K, Casarsa C, Giorgio M, Luscher TF, Pelicci PG, Anversa P, Leri A, Kajstura J. (2006) Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res 99: 42-52
6. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di AE, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-Analysis of 102 prospective studies. Lancet 375:2215-2222
7. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. (2008) Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: A population study of 3.3 million people. Circulation 117: 1945-1954
8. Spencer EA, Pirie KL, Stevens RJ, Beral V, Brown A, Liu B, Green J, Reeves GK. (2008) Diabetes and modifi able risk factors for cardiovascular disease: The prospective Million Women Study. Eur J Epidemiol 23:793-799
9. Herman WH, Zimmet P. (2012) Type 2 diabetes: An epidemic requiring global attention and urgent action. Diabetes Care 35:943-944
10. King H, Aubert RE, Herman WH. (1998) Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431
11. Stoy J, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A, Below JE, Hayes MG, Cox NJ, Lipkind GM, Lipton RB, Greeley SA, Patch AM, Ellard S, Steiner DF, Hattersley AT, Philipson LH, Bell GI. (2007) Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A 104: 15040-15044
12. Chang CL, Chen YC, Chen HM, Yang NS, Yang WC. (2013) Natural cures for type 1 diabetes: A review of phytochemicals, biological actions, and clinical potential. Curr Med Chem 20:899-907
13. Simsek DG, Aycan Z, Ozen S, Cetinkaya S, Kara C, Abali S, Demir K, Tunc O, Ucakturk A, Asar G, Bas F, Cetinkaya E, Aydin M, Karaguzel G, Orbak Z, Siklar Z, Altincik A, Okten A, Ozkan B, Ocal G, Semiz S, Arslanoglu I, Evliyaoglu O, Bundak R, Darcan S. (2013) Diabetes care, glycemic control, complications, and concomitant autoimmune diseases in children with type 1 diabetes in Turkey: A multicenter study. J Clin Res Pediatr Endocrinol 5:20-26
14. Mishra PK, Singh SR, Joshua IG, Tyagi SC. (2010) Stem cells as a therapeutic target for diabetes. Front Biosci 15:461-477
15. Nokoff NJ, Rewers M, Cree GM. (2012) The interplay of autoimmunity and insulin resistance in type 1 diabetes. Discov Med 13:115-122
16. Masoudi FA, Inzucchi SE. (2007) Diabetes mellitus and heart failure: Epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 99:113B-132B
17. Mishra PK, Tyagi N, Kumar M, Tyagi SC. (2009) MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 13: 778-789
18. Agyemang C, Kunst AE, Bhopal R, Zaninotto P, Nazroo J, Unwin N, van Valkengoed I, Redekop WK, Stronks K. (2013) A cross- national comparative study of metabolic syndrome among nondiabetic Dutch and English ethnic groups. Eur J Public Health 23:447-452
19. Barengo NC, Trejo R, Sposetti G. (2013) Prevalence of type 2 diabetes in Argentina 1979-2012. Diabetes Metab Res Rev, Epub. July, 16
20. Gable D, Sanderson SC, Humphries SE. (2007) Genotypes, obesity and type 2 diabetes-can genetic information motivate weight loss? A review. Clin Chem Lab Med 45:301-308
21. Zhang Q, Wang Y, Huang ES. (2009) Changes in racial/ethnic disparities in the prevalence of Type 2 diabetes by obesity level among US adults. Ethn Health 14:439-457
22. Mishra PK, Tyagi N, Kundu S, Tyagi SC. (2009) MicroRNAs are involved in homocysteine- induced cardiac remodeling. Cell Biochem Biophys 55:153-162
23. Mishra PK, Tyagi N, Sen U, Joshua IG, Tyagi SC. (2010) Synergism in hyperhomocysteinemia and diabetes: Role of PPAR gamma and tempol. Cardiovasc Diabetol 9:49-61
24. Mishra PK, Metreveli N, Tyagi SC. (2010) MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: A plausible role of dicer and miRNA. Cell Biochem Biophys 57:67-76
25. Mishra PK, Chavali V, Metreveli N, Tyagi SC. (2012) Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: A role of extracellular matrix. Can J Physiol Pharmacol 90:353-360
26. Mishra PK, Kuypers NJ, Singh SR, Leiberh ND, Chavali V, Tyagi SC. (2013) Cardiac Stem Cell Niche, MMP9, and Culture and Differentiation of Embryonic Stem Cells. Methods Mol Biol 1035:153-163
27. Buralli S, Dini FL, Ballo P, Conti U, Fontanive P, Duranti E, Metelli MR, Marzilli M, Taddei S. (2010) Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 105:853-856
28. Bradham WS, Moe G, Wendt KA, Scott AA, Konig A, Romanova M, Naik G, Spinale FG. (2002) TNF-Alpha and myocardial matrix metalloproteinases in heart failure: Relationship to LV remodeling. Am J Physiol Heart Circ Physiol 282:H1288-H1295
29. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106:55-62
30. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, McClister DM Jr, Su H, Gannon J, MacGillivray C, Lee RT, Sinusas AJ, Spinale FG. (2006) Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 290:H232-H239
31. Spinale FG. (2002) Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 90:520-530
32. Romanic AM, Harrison SM, Bao W, Burns- Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL. (2002) Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 54:549-558